A Phosphatidylcholine-Specific Phospholipase C Regulates Activation of p42/44 Mitogen-Activated Protein Kinases in Lipopolysaccharide-Stimulated Human Alveolar Macrophages1 Martha M. Monick,2 Aaron Brent Carter, Gunnar Gudmundsson, Rama Mallampalli, Linda S. Powers, and Gary W. Hunninghake This study uses human alveolar macrophages to determine whether activation of a phosphatidylcholine (PC)-specific phospholipase C (PC-PLC) is linked to activation of the p42/44 (ERK) kinases by LPS. LPS-induced ERK kinase activation was inhibited by tricyclodecan-9-yl xanthogenate (D609), a relatively specific inhibitor of PC-PLC. LPS also increased amounts of diacylglycerol (DAG), and this increase in DAG was inhibited by D609. LPS induction of DAG was, at least in part, derived from PC hydrolysis. Ceramide was also increased in LPS-treated alveolar macrophages, and this increase in ceramide was inhibited by D609. Addition of exogenous C2 ceramide or bacterial-derived sphingomyelinase to alveolar macrophages increased ERK kinase activity. LPS also activated PKC z, and this activation was inhibited by D609. LPS-activated PKC z phosphorylated MAP kinase kinase, the kinase directly upstream of the ERK kinases. LPS-induced cytokine production (RNA and protein) was also inhibited by D609. As an aggregate, these studies support the hypothesis that one way by which LPS activates the ERK kinases is via activation of PC-PLC and that activation of a PC-PLC is an important component of macrophage activation by LPS. The Journal of Immunology, 1999, 162: 3005–3012.
ne of the early and important factors related to the development of the adult respiratory distress syndrome (ARDS)3 is the release of cytokines by alveolar macrophages (1–3). For sepsis-induced ARDS, endotoxin (LPS) is a major stimulus for the release of cytokines by alveolar macrophages and, thereby, an important factor in the development of ARDS (1–3). The best-defined receptor that is utilized by LPS to trigger expression of the cytokine genes in macrophages is CD14 (4, 5). In this setting, LPS interacts with CD14 complexed with the serum protein, LPS-binding protein. This interaction causes tyrosine phosphorylation of a number of cellular proteins and activation of multiple mitogen-activated protein (MAP) kinases (6 –14). There are three important groups of MAP kinases, the p42/44 (ERK) kinases, the c-jun kinases, and the p38 kinases (15). The activation of these MAP kinase pathways appears to be linked to regulation and expression of cytokine genes as well as other important cellular functions (16 –18). However, the mechanisms that result in activation of these kinase pathways by LPS are poorly understood. The focus of this study was to further
Department of Medicine, University of Iowa College of Medicine and Veterans Administration Medical Center, Iowa City, IA 52242 Received for publication June 8, 1998. Accepted for publication December 4, 1998. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by a VA Merit Review grant and by National Institutes of Health Grants HL-37121 and AI-35018 (to G.W.H.) and Grant HL-03860 (to A.B.C.). 2 Address correspondence and reprint requests to Dr. Martha M. Monick, Room 100 EMRB, The University of Iowa Hospitals and Clinics, Iowa City, IA 52242. E-mail address: [email protected]
3 Abbreviations used in this paper: ARDS, adult respiratory distress syndrome; MAP, mitogen-activated protein; ERK kinases, p42/44 kinases; MEK, mitogen-activated protein kinase kinase; PKC protein kinase C; PC-PLC, phosphatidylcholine-specific phospholipase C; D609, tricyclodecan-9-yl xanthogenate; DAG, diacylglycerol; MBP, myelin basic protein; PA, phosphatidic acid; lyso-PC, L-1-palmitoyl-1-14C]lysopalmitoylphosphatidylcholine; PC, phosphatidylcholine; PLD, phospholipase D.
Copyright © 1999 by The American Association of Immunologists
delineate how LPS activates one of the kinase pathways, the ERK kinases, in alveolar macrophages. The pathways by which the ERK kinases may become activated have been studied in a number of cell systems. These kinases are known to be directly activated by mitogen-activated protein kinase kinase, a kinase directly upstream of the ERK kinases (15). The mechanism by which MEK becomes activated varies, depending on the stimulus and the cell type. The best-described pathway involves the sequential activation of ras, raf-1, MEK, and the ERK kinases (15, 19, 20). Ueda et al. (21) described a ras-independent pathway that requires raf-1 and PKC d. Berra et al. (22, 23) used a dominant-negative mutant of PKC z to block serum and TNF activation of the ERK kinases. These studies suggest that there are multiple pathways by which MEK and the ERK kinases can be activated. No studies have determined how LPS activates the ERK kinases, but several studies provided clues that have led to our hypothesis. A study by Grove et al. (24) showed that LPS activated a phosphatidylcholine-specific phospholipase C (PC-PLC) in macrophages. Several studies using other stimuli have linked activation of a PC-PLC to activation of the ERK kinases in other types of cells (25–27). Potentially, downstream of PC-PLC, ceramide may serve as an activator of PKC z. This has been described in a study by Muller et al. (28), which used TNF as a stimulus. Collectively, these observations led us to hypothesize that LPS-induced activation of ERK kinases in alveolar macrophages would be mediated by sequential activation of PC-PLC, induction of cellular diacylglycerol (DAG) and ceramide, and activation of PKC z. We further hypothesized that activation of a PC-PLC would play an important role in the production of cytokines by LPS-treated alveolar macrophages.
Materials and Methods Isolation of human alveolar macrophages Alveolar macrophages were obtained from bronchoalveolar lavage as previously described (29). Briefly, normal volunteers with a lifetime nonsmoking history, no acute or chronic illness, and no current medications 0022-1767/99/$02.00
3006 underwent bronchoalveolar lavage. The lavage procedure used five 25-ml aliquots of sterile, warmed saline in each of three segments of the lung. The lavage fluid was filtered through two layers of gauze and centrifuged at 1500 3 g for 5 min. The cell pellet was washed twice in HBSS without Ca21 and Mg21 and suspended in complete medium, RPMI tissue culture medium (Life Technologies, Gaithersburg, MD) with 5% FCS (HyClone, Logan, UT), and added gentamicin (80 mg/ml). Differential cell counts were determined using a Wright-Giemsa-stained cytocentrifuge preparation. All cell preparations had between 90 and 100% alveolar macrophages. This study was approved by the Committee for Investigations Involving Human Subjects at the University of Iowa.
Immunoprecipitation of ERK kinase and PKC z Alveolar macrophages were cultured in complete medium with or without LPS (1 mg/ml, Sigma, St. Louis, MO), and/or tricyclodecan-9-yl xanthogenate (D609, 100 mM, Calbiochem, San Diego, CA) a relatively specific inhibitor of PC-PLC, (30 –32). In some instances, cells were also exposed to C2 ceramide (16 mM, Biomol, Plymouth Meeting, MA) or bacterialderived sphingomyelinase (0.4 U/ml, Biomol). After culture, cells were lysed on ice for 20 min in 500 ml of lysis buffer (0.05 M Tris (pH 7.4), 0.15 M NaCl, 1% Nonidet P-40, 0.5 M PMSF, 50 mg/ml aprotinin, 10 mg/ml leupeptin, 50 mg/ml pepstatin, 0.4 mM sodium o-vanadate, 10 mM sodium fluoride, and 10 mM sodium pyrophosphate, all from Boehringer Mannheim, Indianapolis, IN). The lysates were then spun at 15,000 3 g for 10 min, and the supernatant was saved. Protein was measured, and 600 mg from each sample were removed for immunoprecipitation. The samples were cleared by incubation for 2 h with 1 mg/sample rabbit IgG and 10 ml/sample GammaBind Sepharose (Pharmacia, Piscataway, NJ). After centrifugation, the supernatants were transferred to a tube containing 3 mg/ sample rabbit anti-ERK Ab (sc-154, Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-PKC z b (sc-216, Santa Cruz Biotechnology) bound to GammaBind Sepharose and rotated at 4°C overnight. The beads were subsequently washed three times with high salt buffer (0.05 M Tris (pH 7.4), 0.50 M NaCl, and 1% Nonidet P-40) and three times with lysis buffer without protease inhibitors. The ERK or PKC z complexes were either released with 23 sample buffer for Western analysis or used to determine kinase activity.
ERK and PKC z kinase activity After immunoprecipitation of ERK or PKC z from alveolar macrophages, the protein-containing pellet was washed twice with kinase buffer (20 mM MgCl2, 25 mM HEPES, 20 mM b-glycerophosphate, 20 mM p-nitrophenylphosphate, 20 mM sodium o-vanadate, and 2 mM DTT). The pellet was then suspended in 20 ml of kinase buffer, and the following were added: 20 mM ATP, 5 mCi of [g-32P]ATP (BLU 002Z, DuPont/NEN, Boston, MA), and 10 mg of myelin basic protein (MBP, Sigma) or in one instance, 8 mg of MEK-1 (55-kDa polyhistidine-tagged fusion protein, Santa Cruz Biotechnology). The reaction was continued for 15 min (ERK kinase) or 30 min (PKC z) at 25°C and then stopped by the addition of 40 ml/sample of 23 sample buffer. The samples were boiled for 5 min and run on a 10% SDS-PAGE gel. The gel was dried, and autoradiography was performed to visualize the 32P-labeled MBP or MEK-1. Densitometry was performed on films, and fold increase was calculated as experimental sample/control sample.
Western analysis To evaluate equal loading of the protein in the kinase activity assay, we performed Western analysis on a portion of the immunoprecipitated kinase. A 15% portion of the total sample was mixed 1:1 with 23 sample buffer (20% glycerol, 4% SDS, 10% 2-ME, 0.05% bromophenol blue, and 1.25 M Tris, pH 6.8; all chemicals from Sigma), loaded onto a 10% SDS-PAGE gel, and run at 30 mA for 3 h. Cell proteins were transferred to nitrocellulose (ECL, Amersham, Arlington Heights, IL) overnight at 30 V. The nitrocellulose was then blocked with 5% milk in Tris-buffered saline with 0.1% Tween 20 (TTBS) for 1 h, washed, and then incubated with the primary Ab (1:1000 dilution, anti-ERK or anti-PKC z from Santa Cruz Biotechnology) for 1 h. The blots were washed four times with TTBS and incubated for 1 h with horseradish peroxidase-conjugated anti-rabbit IgG Ab (Amersham, at 1/5000 dilution). Immunoreactive bands were developed using a chemiluminescent substrate (ECL, Amersham). Autoradiography was performed, with exposure times of 10 s–2 min, which were adequate for visualization.
Detection of ceramide and DAG The ceramide and DAG mass were evaluated by a slight modification of the procedure as described by Preiss et al. (33). Lipids were extracted from
LPS ACTIVATES p42 MAP KINASE VIA A PC-PLC alveolar macrophages as described, after exposure to medium alone (control), LPS (1 mg/ml), or LPS and D609 (100 mM); dried under nitrogen gas; and solubilized in an aliquot of octyl-b-D-glucoside-cardiolipin solution. The lipid mixture contained 31 ml of 3.19 mM cardiolipin, 10 ml of a 15% octy-b-D-glucoside solution, and 20 ml of 1 mM DETAPAC (all from Sigma). After drying, 20 ml of DETAPAC were added, and the solution was sonicated briefly in a bath sonicator. Fifty microliters of 23 reaction buffer (100 mM imidazole, 100 mM NaCl, 25 mM MgCl2, 2 mM EGTA, pH 6.6), 10 ml of 20 mM DTT, and 10 ml of diluted diacylglycerol kinase membranes were then added to the assay mixture. The reaction was initiated by the addition of 10 ml of a [g-32P]ATP solution. The remainder of the procedure was performed as described (23). The DAG kinase phosphorylates both ceramide and DAG, converting the lipids to ceramide phosphate and phosphatidic acid (PA), respectively. These species were resolved using TLC (ceramide phosphate (Rf 5 0.14) and DAG (Rf of PA 5 0.35)). The films were analyzed with densitometry, and fold increase was calculated as experimental sample/control sample.
Detection of DAG in phosphatidylcholine-labeled cells To evaluate DAG in labeled cells, the following methods were utilized. Alveolar macrophages were cultured overnight in complete medium with added [1-14C]arachidonic acid (NEC661, Dupont/NEN), 0.1 mCi/ 107 cells, or L-1-palmitoyl-1-14C]lysopalmitoylphosphatidylcholine (lyso-PC, NEC683, DuPont/NEN), 0.1 mCi/107 cells. The cells were then washed with PBS and resuspended at 107 cells/ml of complete medium and placed at 1 ml/tube in 1.5-ml microtubes. After stimulation with LPS (1 mg/ml) or LPS and D609 (100 mM) for 5 min, lipids were extracted using the Bligh-Dyer method (34). After extraction, samples were dried under nitrogen gas and resuspended in 50 ml/sample chloroform-methanol (2:1). Samples were then spotted on a TLC plate, (LK 5D, Whatman, Clifton, NJ) and run in a solvent of hexane-diethyl ether-acetic acid (60: 40:1). The DAG bands were found by comparison with the position of a known standard (1,2-dioleolyl-sn-glycerol, C18:1, cis-9, Sigma). Quantitation was done, by analyzing the TLC plate on an AMBIS radioisotope scanner (Scanalytics, Billerica, MA). Data are presented as fold increase, experimental sample/control sample. To confirm that the palmitoyl-1-14C lyso-PC label remained in the phosphatidylcholine (PC) fraction during the 24-h labeling incubation, we evaluated the distribution of the label immediately before the LPS stimulation. Alveolar macrophages were labeled overnight with palmitoyl-1-14C lyso-PC, and then lipids extracted using the Bligh-Dyer method. The major phospholipids (PC, sphingomyelinase, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol) were resolved using TLC in chloroform-methanolacetic acid-water-acetone (40:25:4:2:4). The phospholipids that comigrated with known standards were scraped, and counts were determined using a liquid scintillation counter.
Expression of cytokine mRNA Whole-cell RNA was isolated using RNA Stat-60 according to the manufacturer’s instructions (Tel-Test “B,” Friendswood, TX). Cells were lysed in RNA Stat-60 solution, containing phenol and guanidinium thiocyanate. The mixture was then shaken vigorously, allowed to sit for 2–3 min, and then centrifuged at 12,000 rpm for 15 min at 4°C. The RNA was removed from the upper aqueous layer, precipitated with isopropanol for 30 min, centrifuged at 12,000 rpm for 10 min at 4°C, and washed with 75% ethanol. The isolated RNA was fractionated in a 1.5% denaturing agarose gel containing 2.2 M formaldehyde. An RNA ladder (0.24 –9.5 kb; Life Technologies) was included as a molecular size standard. RNA loading was confirmed by equivalent ethidium bromide staining in each lane. The RNAs were transferred to GeneScreen Plus (DuPont/NEN) as suggested by the manufacturer. IL-6 and TNF cDNA probes (generated by PCR with primers obtained from Clontech, Palo Alto, CA) were labeled with [g-32P]CTP (DuPont/NEN) by random primer method. Blots were prehybridized for 3 h at 42°C (10 ml formamide, 5 mM NaCl, 4 ml 50% dextran, 10% SDS, 1 M Tris (pH 7.0), and 0.4 ml of 503 Denhardt’s solution) and then hybridized with the labeled probe overnight at 42°C. The filters were washed twice with 13 SSC at 25°C, twice with 13 SSC plus 1% SDS at 65°C, and then once with 0.13 SSC at 25°C. The filters were exposed to autoradiographic film at 270°C.
Release of cytokines For these studies, alveolar macrophages were cultured in RPMI medium with 5% FCS for 24 h in the presence or absence of LPS and with and without D609, as described above. After the culture period, the supernatants were harvested and stored at 270° until assayed. The amounts of IL-6 and TNF in the supernatant of the cells were measured by ELISA (R&D Systems, Minneapolis, MN).
The Journal of Immunology
FIGURE 2. LPS-induced ERK 2 kinase activity is not inhibited by propranolol. Alveolar macrophages were cultured with and without LPS (1 mg/ml), propranolol (100 mM), and D609 (100 mM). ERK 2 protein was then immunoprecipitated from the cells and incubated with MBP under phosphorylating conditions. This shows an autoradiograph of radiolabeled MBP run out on a SDS gel.
FIGURE 1. LPS increases ERK 2 kinase activity in alveolar macrophages, and this is inhibited by D609. A, Alveolar macrophages were cultured with and without LPS (1 mg/ml) and D609 (100 mM). ERK 2 protein was then immunoprecipitated from the cells and incubated with MBP under phosphorylating conditions. The top bands show an autoradiograph of radiolabeled MBP run out on a SDS gel. The lower bands show a Western blot of the immunoprecipitated ERK 2 proteins, showing equal loading of the kinase in the assay. B, Densitometry was performed on three experiments, and calculations were made using the mean gray level values, p, p , 0.05 for LPS compared with control and LPS compared with LPS and D609.
Statistical analysis All of the cytokine measurements and densitometry data are shown as means 6 SEM. Statistical comparisons were performed using a paired t test with a probability value of p , 0.05 considered to be significant.
and kinase activity was evaluated using MBP as a substrate. LPS induced activation of the ERK 2 kinase, and D609 blocked activation of this kinase to near baseline levels (Fig. 1A). A Western blot shows equal loading of the kinase in the activity assay. Fig. 1B shows composite data from three separate experiments. These data suggest that PC-PLC activation is an important step in the upregulation of ERK activity in LPS-treated alveolar macrophages. To further confirm that PC-PLC was linked to ERK 2 activation, we evaluated whether phospholipase D (PLD) was linked to ERK 2 activation. To evaluate this, we first determined whether propranolol, an inhibitor of PA phosphohydrolase, blocked ERK 2 activation (35). Propranolol did not inhibit LPS-induced ERK 2 activation (Fig. 2). This observation suggests that PLD-derived DAG is not linked to ERK 2 activation. We also used 2,3-bisdiphosphoglycerate, an inhibitor of PLD (36). This compound also did not inhibit LPS-induced ERK 2 activation (data not shown). This observation suggests that neither activation of PLD nor PLDderived PA is linked to LPS-induced ERK 2 activation. LPS induces activation of PC-PLC We next determined whether LPS stimulates PC-PLC activity and whether this effect is inhibited by D609. We first determined whether LPS increased DAG mass and whether this increase could be blocked by D609. Alveolar macrophages were cultured with or without LPS (1 mg/ml) for 1–5 min and with and without D609 (100 mM) which was added to the cells 30 min before LPS. The cells were harvested, and DAG mass was determined. LPS increased DAG by 1 min after LPS exposure, with a significantly greater increase at 5 min (Fig. 3). The LPS-induced increase in DAG was inhibited by D609. These data show that LPS triggers release of DAG in alveolar macrophages and that DAG might be derived from PC.
D609 blocks activation of the ERK 2 (p42) MAP kinase in alveolar macrophages Although prior studies showed that LPS activates ERK kinases in murine macrophages and human monocytes (9, 10, 12), no studies have shown that LPS activates these kinases in human alveolar macrophages. Thus, we first showed that LPS activates the ERK 2 MAP kinase in alveolar macrophages (Fig. 1). No prior studies have determined whether activation of a PCPLC is linked to activation of the ERK kinases in LPS-stimulated cells. To evaluate the role of PC-PLC on this activation, we cultured alveolar macrophages with and without D609 (100 mM) for 30 min and then stimulated the cells with medium alone (control) or LPS (1 mg/ml) for 15 min. Preliminary data (not shown) showed that LPS-induced ERK 2 kinase activity can be detected as early as 5 min after stimulation and is maximally expressed by 15 min. The cells were then harvested, ERK 2 kinase was immunoprecipitated,
FIGURE 3. LPS increases amounts of DAG, and this is inhibited by D609. Alveolar macrophages were cultured with and without LPS (1 mg/ ml) and D609 (100 mM). Lipids were extracted, and DAG mass was determined. The is an autoradiograph of a TLC plate, showing radiolabeled DAG after experimental treatment with DAG kinase and [g-32P]ATP. Values are representative of three separate experiments.
FIGURE 4. LPS increases amounts of 14C-labeled DAG in cells labeled with [14C]lyso-PC. Alveolar macrophages were labeled with [14C]lyso-PC or [14C]AA and then cultured with or without LPS (1 mg/ml). Lipids were extracted, and increases in amounts of radiolabeled DAG were determined with TLC. An autoradiograph was made of the TLC plate, and densitometry was performed on the resulting image. Fold increase was determined by dividing experimental values by control values.
We next determined whether the DAG was secondary to PC hydrolysis, using a PC-specific label. To perform these experiments, we cultured alveolar macrophages overnight in the presence of [14C]lyso-PC or [14C]arachidonic acid. After removal of the unincorporated label, the cells were stimulated with LPS (1 mg/ml) for 0.25 to 5 min. The cells were then harvested, and DAG levels were determined by separating the lipids on TLC plates (Fig. 4). LPS increased amounts of DAG, and the DAG was derived, at least in part, from PC because increases in labeled DAG were found after using the lyso-PC label. The amount of DAG detected using this label was similar to that detected using [14C]arachidonic acid, as a label. We next determined the distribution of [14C]lysoPC into major phospholipids. We observed that the majority of the label incorporated into PC and, to a lesser extent, sphingomyelinase; only a small percentage of the label was found in the other phospholipids (Fig. 5). The amount of the label in the phospholipids other than PC is unlikely to account for the increases seen in DAG, especially considering that PC is the major phospholipid found in eukaryotic cells. Thus, these results, taken together, suggest that the majority of DAG is derived from PC. LPS increases ceramide in alveolar macrophages Activation of PC-PLC can be linked to activation of sphingomyelinase activity (37, 38). To evaluate this, alveolar macrophages were cultured with medium alone (control) or with LPS (1 mg/ml) for 30 s–30 min. The cells were then harvested, and the amount of ceramide in cell lysates was determined. LPS increased amounts of ceramide in alveolar macrophages as early as 30 s after stimulation with a return to baseline by 30 min after stimulation (Fig. 6). We FIGURE 6. LPS increases amounts of ceramide. Alveolar macrophages were cultured with and without LPS for various time periods. Lipids were extracted and ceramide mass was determined. A, Autoradiograph of a TLC plate, showing 32P-labeled ceramide from cellular lysates. B, Autoradiograph of a TLC plate, showing 32P-labeled C6 ceramide that has gone through the same assay procedure. Densitometry was performed on autoradiographs of the TLC plates, and fold increase calculated as experimental values divided by control values. Values are representative of three separate experiments.
LPS ACTIVATES p42 MAP KINASE VIA A PC-PLC
FIGURE 5. After 24 h of labeling with [14C]lyso-PC, the majority of the label incorporates into PC. Alveolar macrophages were labeled with [14C]lyso-PC overnight, and then lipids were extracted and distribution in the major phospholipid species was determined. PG, phosphatidylglycerol; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin.
next determined whether the LPS induction of ceramide was linked to activation of PC-PLC. Alveolar macrophages were incubated with and without D609 (100 mM, for 30 min) and then stimulated with LPS (1 mg/ml) for 1 or 5 min. The cells were then harvested, and amounts of ceramide were evaluated in cell lysates. D609 blocked the LPS-induced increase in ceramide to below baseline levels (Fig. 7). These data suggest that LPS activates a sphingomyelinase pathway in alveolar macrophages in a PC-PLCdependent manner. Products of the sphingomyelinase pathway activate ERK kinase in alveolar macrophages To determine whether products of the sphingomyelin/ceramide pathway could induce ERK kinase activity in alveolar macrophages, the cells were cultured with medium alone (control), or with C2 ceramide (16 mM), or with bacterial-derived sphingomyelinase (0.4 U/ml) for 5 min or for 1 h. Both C2 ceramide and bacterial-derived sphingomyelinase triggered activation of the ERK kinase by 5 min (Fig. 8). This kinase activity was decreased by 1 h. Shown for comparison are the effects of LPS, which has a more prolonged time course. These studies show that components of the sphingomyelinase pathway can activate ERK kinases in alveolar macrophages. We also asked whether D609 had a nonspecific effect on inhibition of ERK 2. To do this, we incubated alveolar macrophages with C2 ceramide and evaluated the effect of D609 on activation of ERK 2. D609 did not inhibit the activity of C2 ceramide (Fig. 9). This observation suggests that activation of PC-PLC is a proximal event to generation of ceramide. These data also show that D609 does not have a nonspecific effect on ERK 2 activation.
The Journal of Immunology
FIGURE 9. D609 does not block C2 ceramide induced ERK 2 kinase activity in alveolar macrophages. Alveolar macrophages were cultured with C2 ceramide (16 mM) with and without D609 (100 mM). ERK 2 protein was then immunoprecipitated from the cells and incubated with MBP under phosphorylating conditions. This shows an autoradiograph of radiolabeled MBP run out on a SDS gel. FIGURE 7. LPS induction of ceramide is inhibited by D609. Alveolar macrophages were cultured with and without LPS (1 mg/ml) and D609 (100 mM). Lipids were extracted, and ceramide mass was determined. This shows an autoradiograph of the TLC plate, showing 32P-labeled ceramide from cellular lysates. Densitometry was performed on the autoradiograph, and fold increase was calculated as experimental values divided by control values. Values are representative of three separate experiments.
LPS activates PKC z in alveolar macrophages, and this activation is blocked by D609 One means by which ceramide might activate the ERK kinases is via activation of an atypical PKC isoform (z or i) (39). In previous studies, we were able to detect PKC z but not PKC i in alveolar macrophages (40). To determine activation of PKC z, we cultured alveolar macrophages with and without LPS (1 mg/ml) and with and without D609 (100 mM). After 15 min, the cells were harvested, and PKC z was immunoprecipitated from the cell lysates. Fig. 10A shows two different kinase activity assays, one using MBP as a substrate and the other using MEK as a substrate. We also looked at PKC z autophosphorylation with similar results (data not shown). Fig. 10B shows the composite data from three separate experiments, which use MBP as a substrate. These studies show that LPS causes activation of PKC z and that this activation is blocked by D609. These experiments also show that LPS-activated PKC z can phosphorylate the cellular substrate MEK, a kinase directly upstream of the ERK kinases.
and TNF mRNA and protein release. LPS increased both IL-6 and TNF mRNAs and protein release, and these were blocked by D609 (Figs. 11 and 12). These studies show that activation of a PC-PLC can be linked to a physiologically relevant macrophage function (cytokine production after LPS exposure).
Discussion This study was undertaken to define pathways by which LPS might activate the ERK kinases in alveolar macrophages. We hypothesized that LPS activates a PC-PLC, leading to production of DAG, an activator of sphingomyelinase activity. This, in turn, results in increased amounts of ceramide, an important effector molecule, which activates PKC z. PKC z activates MEK, which subsequently leads to ERK kinase activation. To test this hypothesis, we showed that LPS activates the ERK 2 kinase in alveolar macrophages and
D609 blocks LPS-induced release of cytokines To determine whether D609 would interfere with a macrophage function that can be tied to ERK kinase activation (41), we evaluated the effect of D609 on cytokine release and mRNA production in LPS-treated alveolar macrophages. IL-6 and TNF are both proinflammatory cytokines that are released from LPS-activated alveolar macrophages. We evaluated the effect of D609 on IL-6
FIGURE 8. C2 ceramide and sphingomyelinase increase ERK 2 kinase activity in alveolar macrophages. Alveolar macrophages were cultured with C2 ceramide (16 mM), bacterial-derived sphingomyelinase (0.4 U/ml) or LPS (1 mg/ml). ERK 2 protein was then immunoprecipitated from the cells and incubated with MBP under phosphorylating conditions. This shows an autoradiograph of radiolabeled MBP run out on a SDS gel. Values are representative of three experiments.
FIGURE 10. LPS increases PKC z activity in alveolar macrophages, and this is inhibited by D609. A, Alveolar macrophages were cultured with and without LPS (1 mg/ml) or D609 (100 mM). PKC z was then immunoprecipitated and incubated with either MBP (top bands) or MEK-1 (lower bands) under phosphorylating conditions. This is an autoradiograph of radiolabeled MBP (top) or MEK (bottom) run out on a SDS gel. B, Densitometry was performed on the autoradiographs from three experiments that utilized MBP as a substrate; p , 0.05 for LPS compared with control and LPS compared with LPS and D609.
FIGURE 11. D609 blocks cytokine mRNA production in LPS-treated alveolar macrophages. Alveolar macrophages were cultured with and without LPS (1 mg/ml) or D609 (100 mM). After 3 h of culture, whole cell RNA was isolated and Northern analysis was performed. Blots were probed with radiolabeled cDNA specific for IL-6 (top bands) and TNF (middle bands), and an autoradiograph was obtained. Ethidium bromide staining of ribosomal bands is included (bottom bands) to show equal loading of the RNA in the blot.
that this activation is inhibited by D609, a relatively specific inhibitor of PC-PLC. We next showed that LPS increases amounts of DAG and ceramide and that both of these effects of LPS are inhibited by D609. Our present studies indicate that LPS induction of DAG in alveolar macrophages is derived, at least in part, from a PC-containing phospholipid. Thus, we conclude from these experiments that the LPS-induced DAG is derived from hydrolysis of PC via activation of PC-PLC. In separate studies, the addition of exogenous C2 ceramide or bacterial-derived sphingomyelinase activated ERK 2 kinase in alveolar macrophages, and this activation was not inhibited by D609. Finally, we showed that LPS activates PKC z, and that PKC z from LPS-treated cells can activate MEK. The LPS-induced activation of PKC z also was inhibited by D609. Collectively, these studies strongly suggest that LPS activates the ERK kinases in alveolar macrophages via sequential activation of
LPS ACTIVATES p42 MAP KINASE VIA A PC-PLC a PC-PLC, sphingomyelin hydrolysis, and PKC z. We have not proved that this is the only pathway by which LPS activates ERK kinases, but our studies strongly support the hypothesis that this is an important effector mechanism by which LPS activates ERK kinases in alveolar macrophages. We further show that LPS activation of a PC-PLC is linked to important macrophage functions, because inhibition of PC-PLC interferes with cytokine production in LPS-treated alveolar macrophages. Several studies support the idea that hydrolysis of PC is coupled to activation of ERK kinases. Cai et al., using NIH 3T3 cells, have shown that the addition of exogenous PC-PLC induces phosphorylation of MEK, which subsequently activates ERK kinases (25). In fibroblasts (Rat-1), van Dijk et al. (26) have shown that stimulation of PC-PLC activity results in activation of the ERK kinases. Work by Sands et al. (42) suggests that PC hydrolysis might be a relevant signaling pathway in endotoxin-exposed macrophages. Using murine macrophages, LPS treatment increased DAG, which was due to activation of PC-PLC. These studies are consistent with our finding that LPS activates ERK kinases in alveolar macrophages via an activation of PC-PLC. Our observation that LPS activation of a sphingomyelinase pathway by PC-PLC-generated DAG is supported by studies evaluating TNF and IL-1 signaling in a variety of cell types (reviewed by Kolesnick and Golde (43)). Several studies have linked generation of DAG to activation of a sphingomyelinase activity and subsequent ceramide generation. Of special relevance to our studies are the observations of Lozano et al. (39) and Muller et al. (28) which reported that the addition of exogenous sphingomyelinase to cells activates PKC z (Lozano), and that PKC z is activated by ceramide (Muller). These studies are consistent with our findings for both ceramide generation and PKC z activation in LPS-treated alveolar macrophages. These results are also in agreement with prior studies, which link PC-PLC to PKC z and ERK kinase activation. Bjorkoy et al. (44) have shown in NIH 3T3 cells that PKC z activation is a necessary downstream component of PC-PLC cell transformation. A study by van Dijk et al. (26) used an inhibitor of PKC (Ro318220) to block PC-PLC-induced MAP kinase activation. They showed that expression of a dominant negative mutant of PKC z,
FIGURE 12. D609 blocks release of IL-6 and TNF protein from LPS-treated alveolar macrophages. Alveolar macrophages were cultured with and without LPS (1 mg/ml) or D609 (100 mm). After 24 h in culture, the supernatant was removed, and cytokine levels were determined by ELISA. Statistical analysis was done using a paired t test. p, p , 0.05; pp, p , 0.01.
The Journal of Immunology unlike down-regulation of other PKC isoforms (a, d, and e), inhibited the MAP kinase activation by PC-PLC. Berra et al. (23) also showed that a dominant negative mutant of PKC z dramatically impaired the activation of both MEK and MAP kinase in serum- and TNF-treated COS cells. These studies are consistent with our finding that PKC z plays a central role in ERK kinase activation by LPS in alveolar macrophages. DAG, phosphatidic acid, or ceramide have all been shown to stimulate PKC z in vitro (26, 28, 45). The observation that neither propranolol nor 2,3-bisdiphosphoglycerate inhibits LPS-induced ERK 2 activation argues that PA is of little importance in this system. In addition, the observation that ceramide inhibits DAG kinase suggests that PCPLC-derived PA might be limiting and therefore of lesser importance in LPS induction of PKC z activity (46). Aside from LPS activation of MEK via PKC z, a number of studies suggest a role for Raf-1 in ERK kinase activation. One possible parallel pathway could include LPS3 PC-PLC3 DAG3novel PKC isoform3raf-13 MEK3 ERK. This pathway is suggested in studies where dominant-negative mutants of raf-1 inhibited signaling through PC-PLC (25). Other studies demonstrate that LPS causes phosphorylation and activation of Raf-1, which was temporally associated with activation of MEK and ERK (12). These data suggest that LPS also could activate ERK kinases through a raf-1-dependent pathway. To our knowledge, prior studies have not demonstrated that LPS induces ceramide, which was observed in our studies to be PC-PLC dependent and capable of activating the ERK kinase pathway. Ceramide can also directly activate raf-1 (47). Thus, our data suggest a third possible pathway: LPS3 PC-PLC3 DAG3ceramide3raf13 MEK3 ERK. A recent paper by Luberto et al. (48) suggests a related possibility for the sequence of events involved in LPS signaling. This study suggests that PC-PLC might also function as a sphingomyelin synthase and/or that D609 cannot distinguish between the enzymatic activities of sphingomyelin synthase and PC-PLC. Thus, it is possible that activation of PKC z and ERK 2 could result from activation of a sphingomyelin synthase rather than a PC-PLC. Thus, further studies are necessary to determine whether LPS-induced activation of ERK 2 is linked to a PC-PLC or a sphingomyelin synthase. A novel conclusion of these studies is that activation of a PC-PLC or a sphingomyelin synthase by LPS is critical for activation of the ERK kinases. The importance of this observation is strengthened by the recent observations of Machleidt et al. (49), who showed that inhibition of PC-PLC by D609 markedly diminished the manifestations of sepsis (endotoxin) in an animal model of sepsis.
References 1. Chollet-Martin, S., B. Jourdain, C. Gibert, C. Elbim, J. Chastre, and M. A. Gougerot-Pocidalo. 1996. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am. J. Respir. Crit. Care Med. 153: 594. 2. Goodman, R. B., R. M. Strieter, D. P. Martin, K. P. Steinberg, J. A. Milberg, R. J. Maunder, S. L. Kunkel, A. Walz, L. D. Hudson, and T. R. Martin. 1996. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154:602. 3. Baughman, R. P., K. L. Gunther, M. C. Rashkin, D. A. Keeton, and E. N. Pattishall. 1996. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am. J. Respir. Crit. Care Med. 154:76. 4. Deutener, M. A., V. Bazil, E. VonAsmuth, M. Ceska, and W. A. Buurman. 1993. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-a, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J. Immunol. 150:2885. 5. Viriyakosol, S., and T. N. Kirkland. 1995. A region of human CD14 required for lipopolysaccharide binding. J. Biol. Chem. 270:361. 6. Arditi, M., J. Zhou, M. Torres, D. L. Durden, M. Stins, and K. S. Kim. 1995. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14dependant manner. J. Immunol. 155:3994. 7. Geng, Y., B. Zhang, and M. Lotz. 1993. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J. Immunol. 151:6692.
3011 8. Hambleton, J., S. L. Weinstein, L. Lem, and A. L. DeFranco. 1996. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc. Natl. Acad. Sci. USA 93:2774. 9. Hambleton, J., M. McMahon, and A. L. DeFranco. 1995. Activation of raf-1 and mitogen-activated protein kinase in murine macrophages partially mimics lipopolysaccharide-induced signalling events. J. Exp. Med. 182:147. 10. Liu, M. K., P. Herrera-Velit, R. W. Brownsey, and N. E. Reiner. 1994. CD14dependent activation of protein kinase C and mitogen-activated protein kinases (p42 and p44) in human monocytes treated with bacterial lipopolysaccharide. J. Immunol. 153:2642. 11. Nick, J. A., N. J. Avdi, P. Gerwins, G. L. Johnson, and G. S. Warthen. 1996. Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J. Immunol. 156:4867. 12. Reimann, T., D. Buscher, R. A. Hipskind, S. Krautwald, M. L. LohmannMatthes, and M. Baccharini. 1994. Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. J. Immunol. 153:5740. 13. Sanghera, J. S., S. L. Weinstein, M. Alvwalia, J. Girn, and S. L. Pelech. 1996. Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages. J. Immunol. 156:4457. 14. Weinstein, S. L., J. S. Sanghera, K. Lemke, A. L. DeFranco, and S. L. Pelech. 1992. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem. 267: 14955. 15. Seger, R., and E. G. Krebs. 1995. The MAPK signaling cascade. FASEB J. 9:726. 16. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, J. E. Strickler, M. M. McLaughlin, I. R. Siemens, S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, and P. R. Young. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739. 17. Lee, J. C., and P. R. Young. 1996. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 59:152. 18. Davis, R. J. 1993. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553. 19. Bokemeyer, D., A. Sorokin, and M. J. Dunn. 1996. Multiple intracellular MAP kinase signaling cascades. Kidney Int. 49:1187. 20. Winitz, S., M. Russell, N. Qian, A. Gardner, L. Dwyer, and G. L. Johnson. 1993. Involvement of ras and raf in the Gi-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. J. Biol. Chem. 286:19196. 21. Ueda, Y., S. Hiraai, S. Osada, A. Suzuki, K. Mizuno, and S. Ohno. 1996. Protein kinase C d activates the MEK-ERK pathway in a manner independent of ras and dependent on raf. J. Biol. Chem. 271:23512. 22. Berra, E., M. T. Diaz-Meco, I. Dominguez, M. M. Municio, L. Sanz, and J. Moscat. 1993. Protein kinase z isoform is critical for mitogenic signal transduction. Cell 74:555. 23. Berra, E., M. T. Diaz-Meco, J. Lozano, S. Frutos, M. M. Municio, P. Sanchez, L. Sanz, J. Moscat. 1995. Evidence for a role of MEK and MAPK during signal transduction by protein kinase C z. EMBO J. 14:6157. 24. Grove, R. I., N. J. Allegretto, P. A. Kiener, and G. A. Warr. 1990. Lipopolysaccharide (LPS) alters phosphatidylcholine metabolism in elicited peritoneal macrophages. J. Leukoc. Biol. 48:38. 25. Cai, H., P. Erhardt, J. Troppmair, M. T. Diaz-Meco, G. Sithanandam, V. R. Rapp, J. Moscat, and G. M. Cooper. 1993. Hydrolysis of phosphatidylcholine couples ras to activation of raf protein kinase during mitogenic signal transduction. Mol. Cell. Biol. 13:7645. 26. van Dijk, M. C., F. J. Muriana, P. C. van Der Hoeven, J. de Widt, D. Schaap, W. H. Moolenaar, and W. J. van Blitterswijk. 1997. Diacylglycerol generated by exogenous phospholipase C activates the mitogen-activated protein kinase pathway independent of Ras- and phorbol ester-sensitive protein kinase C: dependence on protein kinase C-z. Biochem. J. 323:693. 27. van Dijk, M. C., F. J. Muriana, J. de Widt, H. Hijkmann, and W. J. van Blitterswijk. 1997. Involvement of phosphatidylcholine-specific phospholipase C in platelet-derived growth factor-induced activation of the mitogenactivated protein kinase pathway in rat-1 fibroblasts. J. Biol. Chem. 272:11011. 28. Muller, G., M. Ayoub, P. Storz, J. Rennecke, D. Fabbro, and K. Pfizenmaier. 1995. PKCz is a molecular switch in signal transduction of TNF-a, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14:1961. 29. Zavala, D., and G. W. Hunninghake. 1983. Lung lavage. In Recent Advances in Respiratory Medicine. D. C. Glenley and T. L. Petty, eds. Churchill Livingston, Edinburgh, p. 21. 30. Cowen, D. S., R. S. Sowers, and D. R. Manning. 1996. Activation of a mitogenactivated protein kinase (ERK 2) by the 5-hydroxytryptamine1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis. J. Biol. Chem. 271:22297. 31. Muller-Decker, K. 1989. Interruption of TPA-induced signal by an antiviral and antitumoral xanthate compound: inhibition of a phospholipase C-type activity. Biochem. Biophys. Res. Commun. 162:198. 32. Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wiegmann, and M. Kronke. 1992. TNF activates NF-kB by phosphatidylcholine-specific phospholipase C induced “acidic” sphingomyelin breakdown. Cell 71:765. 33. Preiss, J., C. R. Loomis, W. R. Bishop, R. Stein, J. E. Niedel, and R. M. Bell. 1986. Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes and ras- and sis- transformed normal rat kidney cells. J. Biol. Chem. 261:8597. 34. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:911.
3012 35. Balboa, M. A., J. Balsinde, and E. A. Dennis. 1998. Involvement of phosphatidate phosphohydrolase in arachidonic acid mobilization in human amnionic WISH cells. J. Biol. Chem. 273:7684. 36. Kusner, D. J., C. F. Hall, and L. S. Schlesinger. 1996. Activation of phospholipase D is coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. J. Exp. Med. 184:585. 37. Cifone, M. G., P. Roncaioli, R. DeMaria, G. Camarda, A. Santoni, G. Ruberti, and R. Testi. 1995. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidyl choline-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14:5859. 38. Ballou, L. R., S. J. Laulederkind, E. F. Rosloniec, and R. Raghow. 1996. Ceramide signaling and the immune response. Biochim. Biophys. Acta 1301:273. 39. Lozano, J., E. Berra, M. M. Municio, M. T. Diaz-Meco, I. Dominguez, L. Sanz, and J. Moscat. 1994. Protein kinase C z isoform is critical for kB-dependent promoter activation by sphingomyelinase. J. Biol. Chem. 269:19200. 40. Monick M. M., A. B. Carter, G. Gudmundsson, L. J. Geist, and G. W. Hunninghake. 1998. Changes in PKC isoforms in human alveolar macrophages compared to blood monocytes. Am. J. Physiol. (Lung Cell. Mol. Physiol.) 275:L389. 41. Carter, A. B., M. M. Monick, and G. W. Hunninghake. 1999. Both ERK and p38 kinases are necessary for cytokine gene expression. Am. J. Respir. Cell Mol. Biol. In press. 42. Sands, W. A., J. S. Clark, and F. Y. Liew. 1994. The role of a phosphatidylcholine-specific phospholipase C in the production of diacylglycerol for nitric oxide synthesis in macrophages activated by IFN-g and LPS. Biochem. Biophys. Res. Commun. 199:461.
LPS ACTIVATES p42 MAP KINASE VIA A PC-PLC 43. Kolesnick, R., and D. W. Golde. 1994. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77:325. 44. Bjorkoy, G., A. Overvatn, M. T. Diaz-Meco, J. Moscat, and T. Johansen. 1995. Evidence for a bifurcation of the mitogenic signaling pathway activated by ras and phosphatidylcholine-hydrolyzing phospholipase C. J. Biol. Chem. 270:21299. 45. Limatola, C., D. Schaap, W. H. Moolenaar, and W. J. van Blitterswijk. 1994. Phosphatidic acid activation of protein kinase C-z overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids. Biochem. J. 304:1001. 46. Younes, A., D. W. Kahn, J. M. Besterman, R. Bittman, H. Byun, and R. N. Kolesnick. 1992. Ceramide is a competitive inhibitor of diacylglycerol kinase in vitro and in intact human leukemia (HL-60) cells. J. Biol. Chem. 267: 842. 47. Huwiler, A., J. Brunner, R. Hummel, M. Vervoordeldonk, S. Stabel, H. Van den Bosch, and J. Pfeilschifter. 1996. Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc. Natl. Acad. Sci. USA 93:6959. 48. Luberto, C., and Y. A. Hannun. 1998. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. J. Biol. Chem. 273:14550. 49. Machleidt, T., B. Kramer, D. Adam, B. Neumann, S. Schutze, K. Wiegmann, and M. Kronke. 1996. Function of the p55 tumor necrosis factor receptor “death domain” mediated by phosphatidylcholine-specific phospholipase C. J. Exp. Med. 184:725.